| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study
|
Kleppe, Andreas
|
|
|
23 |
9 |
p. 1221-1232
|
artikel
|
| 2 |
Adjuvant immunotherapy for renal cell carcinoma
|
Sendur, Mehmet Ali Nahit
|
|
|
23 |
9 |
p. 1110-1111
|
artikel
|
| 3 |
A lump in the throat
|
Kaakour, Dalia
|
|
|
23 |
9 |
p. e435
|
artikel
|
| 4 |
Call for action: expanding global access to hereditary cancer genetic testing
|
Bychkovsky, Brittany
|
|
|
23 |
9 |
p. 1124-1126
|
artikel
|
| 5 |
Centralisation of oncology surgery services
|
Sorensen, Jan
|
|
|
23 |
9 |
p. 1119-1121
|
artikel
|
| 6 |
Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial
|
Westeel, Virginie
|
|
|
23 |
9 |
p. 1180-1188
|
artikel
|
| 7 |
Clearing the radiotherapy backlog: innovation to pave the way
|
The Lancet Oncology,
|
|
|
23 |
9 |
p. 1109
|
artikel
|
| 8 |
CNS prophylaxis for diffuse large B-cell lymphoma
|
Eyre, Toby A
|
|
|
23 |
9 |
p. e416-e426
|
artikel
|
| 9 |
Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?
|
Elkrief, Arielle
|
|
|
23 |
9 |
p. 1113-1114
|
artikel
|
| 10 |
Correction to Lancet Oncol 2022; 23: 888–98
|
|
|
|
23 |
9 |
p. e404
|
artikel
|
| 11 |
Correction to Lancet Oncol 2022; 23: 416–27
|
|
|
|
23 |
9 |
p. e404
|
artikel
|
| 12 |
Correction to Lancet Oncol 2022; 23: 1167–79
|
|
|
|
23 |
9 |
p. e404
|
artikel
|
| 13 |
Correction to Lancet Oncol 2022; 23 (Abstracts from the The Lancet Summit: Cancer care in Asia and Latin America Special Issue): S11
|
|
|
|
23 |
9 |
p. e404
|
artikel
|
| 14 |
Correction to Lancet Oncol 2022; 23 (Abstracts from the The Lancet Summit: Cancer care in Asia and Latin America Special Issue): S29
|
|
|
|
23 |
9 |
p. e404
|
artikel
|
| 15 |
Correction to Lancet Oncol 2022; 23: e374–84
|
|
|
|
23 |
9 |
p. e404
|
artikel
|
| 16 |
Customising radiotherapy in stage II breast cancer after primary chemotherapy
|
Kirova, Youlia
|
|
|
23 |
9 |
p. 1118-1119
|
artikel
|
| 17 |
De-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study
|
de Wild, Sabine R
|
|
|
23 |
9 |
p. 1201-1210
|
artikel
|
| 18 |
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial
|
Somaiah, Neeta
|
|
|
23 |
9 |
p. 1156-1166
|
artikel
|
| 19 |
Ethical considerations for the modification of routine human papillomavirus immunisation schedules
|
D'Souza, Jeff
|
|
|
23 |
9 |
p. 1121-1122
|
artikel
|
| 20 |
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial
|
Yamazaki, Tomoko
|
|
|
23 |
9 |
p. 1189-1200
|
artikel
|
| 21 |
Health service planning to assess the expected impact of centralising specialist cancer services on travel times, equity, and outcomes: a national population-based modelling study
|
Aggarwal, Ajay
|
|
|
23 |
9 |
p. 1211-1220
|
artikel
|
| 22 |
Hitting the sweet spot: optimal use of corticosteroids for immune checkpoint inhibitor side-effects
|
Schmitt, Andreas M
|
|
|
23 |
9 |
p. 1123-1124
|
artikel
|
| 23 |
IAEA expresses concern over situation at Zaporizhzya Nuclear Power Plant
|
Das, Manjulika
|
|
|
23 |
9 |
p. 1127
|
artikel
|
| 24 |
IASLC 2022 World Conference on Lung Cancer
|
Geraldes, Flávia Oliveira
|
|
|
23 |
9 |
p. 1128
|
artikel
|
| 25 |
Immune checkpoint inhibition in sarcomas: time to be histology-specific?
|
Napolitano, Andrea
|
|
|
23 |
9 |
p. 1111-1112
|
artikel
|
| 26 |
Inhibiting TGF-β to increase response rates to chemoradiotherapy in rectal cancer
|
Romesser, Paul B
|
|
|
23 |
9 |
p. 1116-1118
|
artikel
|
| 27 |
Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice?
|
Dienstmann, Rodrigo
|
|
|
23 |
9 |
p. 1129-1131
|
artikel
|
| 28 |
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|
Powles, Thomas
|
|
|
23 |
9 |
p. 1133-1144
|
artikel
|
| 29 |
RETRACTED: Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study
|
Dummer, Reinhard
|
|
|
23 |
9 |
p. 1145-1155
|
artikel
|
| 30 |
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
|
Lu, Shun
|
|
|
23 |
9 |
p. 1167-1179
|
artikel
|
| 31 |
Sudan's cancer care in crisis
|
Das, Manjulika
|
|
|
23 |
9 |
p. e405
|
artikel
|
| 32 |
Te Aho o Te Kahu: weaving equity into national-level cancer control
|
Mako, Michelle
|
|
|
23 |
9 |
p. e427-e434
|
artikel
|
| 33 |
Thank you and farewell: cancer control and Japan's former Prime Minister Shinzo Abe
|
Tanaka, Yusuke
|
|
|
23 |
9 |
p. e403
|
artikel
|
| 34 |
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview
|
Giraud, Eline L
|
|
|
23 |
9 |
p. e406-e415
|
artikel
|
| 35 |
Transforming cancer: behind the scenes at the Crick Institute
|
Lucas, Catherine
|
|
|
23 |
9 |
p. 1131-1132
|
artikel
|
| 36 |
What is the best choice of follow-up procedure following resection of lung cancer?
|
Nestle, Ursula
|
|
|
23 |
9 |
p. 1115-1116
|
artikel
|
Tijdschrift beschrijving